Published in Gut Liver on December 17, 2010
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer (2007) 5.38
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 3.59
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol (1990) 3.20
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res (2006) 2.99
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res (2004) 2.66
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther (2006) 2.44
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol (2001) 2.39
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31
Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther (2006) 2.25
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res (2001) 2.24
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res (2002) 2.23
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res (2005) 2.21
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res (1999) 2.20
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A (2007) 2.17
The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med (2009) 2.16
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol (2010) 2.03
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res (2007) 2.00
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol (1984) 1.98
S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res (2005) 1.95
Retracted Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer (2006) 1.89
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol (2002) 1.78
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer (2007) 1.72
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res (1999) 1.67
Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res (2010) 1.66
MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol (2005) 1.65
Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun (2003) 1.65
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Cancer therapy and p53. Curr Opin Oncol (1995) 1.61
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther (2002) 1.58
Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res (2005) 1.58
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res (2005) 1.57
Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res (2006) 1.52
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res (2004) 1.51
Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol (2004) 1.46
Retracted Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer (2006) 1.44
Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg (2006) 1.44
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol (2002) 1.39
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst (2009) 1.35
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol (2006) 1.34
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun (2005) 1.29
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res (2007) 1.27
K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer (2000) 1.27
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest (2004) 1.26
Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg (2007) 1.23
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res (2006) 1.23
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol (2001) 1.22
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer (2003) 1.22
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs (2005) 1.22
The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg (2002) 1.22
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer (2006) 1.20
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther (2005) 1.18
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol (2003) 1.17
p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg (2002) 1.17
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38
The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev (2008) 1.34
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs (2009) 1.19
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs (2009) 1.14
Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07
Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev (2010) 1.06
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Capecitabine: an overview of the side effects and their management. Anticancer Drugs (2008) 1.00
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol (2009) 0.95
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
The role of endobronchial ultrasound in lung cancer diagnosis and staging: a comprehensive review. Clin Lung Cancer (2012) 0.95
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91
Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev (2010) 0.91
Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89
Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89
Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs (2009) 0.88
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88
Role of vitamin d in the prevention of pancreatic cancer. J Nutr Metab (2011) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
Early detection of pancreatic cancer. JOP (2012) 0.87
Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87
Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87
Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87
The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res (2009) 0.86
Quality of life in patients with pancreatic cancer. JOP (2012) 0.86
Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86
From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int (2011) 0.86
Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol (2011) 0.86
Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer (2009) 0.85
Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85
Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85
Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85
Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.85
Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84
Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84
Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol (2010) 0.84
Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84
Advancements in the management of pancreatic cancer. JOP (2009) 0.83
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83
Diabetes and pancreatic cancer. JOP (2014) 0.83
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83
Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83
PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83
First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82
Therapy-induced toxicity of the lungs: an overview. Anticancer Res (2009) 0.82